| Patricia Carabajal, MD | |
|
2121 Juan Tabo Ne, Albuquerque, NM 87112 | |
| (505) 237-8800 | |
| (505) 237-8803 |
| Full Name | Patricia Carabajal |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 39 Years |
| Location | 2121 Juan Tabo Ne, Albuquerque, New Mexico |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255366274 | NPI | - | NPPES |
| 21246 | Medicaid | NM |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 89-15 (New Mexico) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ambercare Home Health | Belen, NM | Home health agency |
| Compassus Home Health Albuquerque Nm | Albuquerque, NM | Home health agency |
| Lovelace Medical Center | Albuquerque, NM | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Optumcare New Mexico Llc | 9032125810 | 68 |
News Archive
Almost one-third of older Americans diagnosed with primary open angle glaucoma (POAG) are not treated medically or surgically for the condition according to a study presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Fort Lauderdale, Fla.
Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.
Researchers studying the molecular signals that drive a specific type of lymphoma have discovered a key biological pathway leading to this type of cancer. Cancerous cells have been described as being "addicted" to certain oncogenes (cancer-causing genes), and the new research may lay the groundwork for breaking that addiction and effectively treating aggressive types of B cell lymphoma.
The Food and Drug Administration has approved the first ceramic-on-metal total artificial hip system for osteoarthritis patients, a device made by Johnson & Johnson's DePuy Orthopaedics unit, the agency said Tuesday. The Pinnacle Complete Acetabular Hip System, combining a ceramic ball and a metal socket, has been sanctioned for people with osteoarthritis, the agency said in a news release.
Sen. Chuck Grassley (R-Iowa) has sent a letter to Merck Chief Operating Officer Richard Clark requesting the company explain a recent report that found the company used employees or paid consultants rather than the physicians listed as lead authors to write several published studies of the COX-2 inhibitor Vioxx, CQ HealthBeat reports.
› Verified 7 days ago
| Entity Name | Optumcare New Mexico Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124053210 PECOS PAC ID: 9032125810 Enrollment ID: O20060302000704 |
News Archive
Almost one-third of older Americans diagnosed with primary open angle glaucoma (POAG) are not treated medically or surgically for the condition according to a study presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Fort Lauderdale, Fla.
Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.
Researchers studying the molecular signals that drive a specific type of lymphoma have discovered a key biological pathway leading to this type of cancer. Cancerous cells have been described as being "addicted" to certain oncogenes (cancer-causing genes), and the new research may lay the groundwork for breaking that addiction and effectively treating aggressive types of B cell lymphoma.
The Food and Drug Administration has approved the first ceramic-on-metal total artificial hip system for osteoarthritis patients, a device made by Johnson & Johnson's DePuy Orthopaedics unit, the agency said Tuesday. The Pinnacle Complete Acetabular Hip System, combining a ceramic ball and a metal socket, has been sanctioned for people with osteoarthritis, the agency said in a news release.
Sen. Chuck Grassley (R-Iowa) has sent a letter to Merck Chief Operating Officer Richard Clark requesting the company explain a recent report that found the company used employees or paid consultants rather than the physicians listed as lead authors to write several published studies of the COX-2 inhibitor Vioxx, CQ HealthBeat reports.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Patricia Carabajal, MD Po Box 27829, Albuquerque, NM 87125 Ph: (505) 232-1920 | Patricia Carabajal, MD 2121 Juan Tabo Ne, Albuquerque, NM 87112 Ph: (505) 237-8800 |
News Archive
Almost one-third of older Americans diagnosed with primary open angle glaucoma (POAG) are not treated medically or surgically for the condition according to a study presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Fort Lauderdale, Fla.
Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.
Researchers studying the molecular signals that drive a specific type of lymphoma have discovered a key biological pathway leading to this type of cancer. Cancerous cells have been described as being "addicted" to certain oncogenes (cancer-causing genes), and the new research may lay the groundwork for breaking that addiction and effectively treating aggressive types of B cell lymphoma.
The Food and Drug Administration has approved the first ceramic-on-metal total artificial hip system for osteoarthritis patients, a device made by Johnson & Johnson's DePuy Orthopaedics unit, the agency said Tuesday. The Pinnacle Complete Acetabular Hip System, combining a ceramic ball and a metal socket, has been sanctioned for people with osteoarthritis, the agency said in a news release.
Sen. Chuck Grassley (R-Iowa) has sent a letter to Merck Chief Operating Officer Richard Clark requesting the company explain a recent report that found the company used employees or paid consultants rather than the physicians listed as lead authors to write several published studies of the COX-2 inhibitor Vioxx, CQ HealthBeat reports.
› Verified 7 days ago
Anne Jones, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 8300 Constitution Ave Ne, Albuquerque, NM 87110 Phone: 505-272-2700 | |
Dr. Matias James Vega, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1217 1st St Nw, Albuquerque Health Care For The Homeless, Albuquerque, NM 87102 Phone: 505-242-4644 Fax: 505-242-3531 | |
Bill Daugherty, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 5901 Harper Dr Ne, Pmg Urgent Care, Albuquerque, NM 87109 Phone: 505-823-8233 Fax: 505-823-8059 | |
Mr. John A Bond, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4420 Irving Blvd Nw, Albuquerque, NM 87114 Phone: 505-727-6300 Fax: 505-727-9588 | |
Margaret Peggy Spencer, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1501 San Pedro Dr Se, Albuquerque, NM 87108 Phone: 505-265-1711 Fax: 505-256-6414 | |
Daniel L. Stulberg, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: Msc 09 5040, 1 University Of New Mexico, Albuquerque, NM 87131 Phone: 505-272-2165 | |
Carrie A Irvin, PA-C Family Medicine Medicare: Medicare Enrolled Practice Location: 1524 Eubank Blvd Ne Ste 6, Albuquerque, NM 87112 Phone: 505-503-8806 Fax: 888-503-8511 |